Peptimmune options AIDS immunity technology from Mass General
Executive Summary
Massachusetts General Hospital gave Peptimmune (drugs based on antigen processing and presentation, the initiating events in the immune response) the option to exclusively license its patent-pending technology regarding replication of the AIDS virus.
Deal Industry
- Pharmaceuticals
-
Pharmaceuticals
- Vaccines
-
Biotechnology
- Large Molecule
Deal Status
- Final
Deal Type
-
Alliance
- R&D and Marketing (Licensing)
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice